Search research articles
Contact Us
Filters
Showing results (211-220 of 261) with videos related to
Page
of 27
Sort By:
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 4, 2018
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer
Clemens Grassberger, Theodore S Hong, Tai Hato, et al.
Oncotarget
|
December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
Yehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2023
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer
Yves Boucher, Jessica M Posada, Sonu Subudhi, et al.
Ejhaem
|
July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
Joan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Ecancermedicalscience
|
December 21, 2016
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai
Pan Pantziarka, Lisa Hutchinson, Nicolas André, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
Sam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 261) with videos related to
Sort By:
Page
of 27
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 4, 2018
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer
Clemens Grassberger, Theodore S Hong, Tai Hato, et al.
Oncotarget
|
December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
Yehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2023
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer
Yves Boucher, Jessica M Posada, Sonu Subudhi, et al.
Ejhaem
|
July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
Joan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Ecancermedicalscience
|
December 21, 2016
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai
Pan Pantziarka, Lisa Hutchinson, Nicolas André, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
Sam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Page
of 27